IN THE CLAIMS

1. (Currently Amended) ~~A~~An isolated protein having an amino acid sequence shown in SEQ ID NO: 1, or a protein having the same amino acid sequence as shown in SEQ ID NO:1 except that one or more amino acids are substituted or deleted, or that one or more amino acids are inserted or added, which has an activity to transfer *N*-acetylglucosamine to a non-reducing terminal of Galβ1-4Glc or Galβ1-4GlcNAc group through β1,3-linkage.

2. (Previously Presented) The protein according to claim 1, which has the amino acid sequence shown in SEQ ID NO: 3, or a protein having the same amino acid sequence as shown in SEQ ID NO: 1 except that one or more amino acids are substituted or deleted, or that one or more amino acids are inserted or added.

3. (Original) The protein according to claim 1 or 2, wherein said protein has an amino acid sequence having a homology of not less than 70% to said amino acid sequence shown in SEQ ID NO:1 or 3.

4. (Original) The protein according to claim 3, wherein said protein has an amino acid sequence having a homology of not less than 90% to said amino acid sequence shown in SEQ ID NO:1 or 3.

5. (Original) The protein according to claim 4, wherein said protein has an amino acid sequence having the same amino acid sequence as shown in SEQ ID NO:1 or 3 except that one or several amino acids are substituted or deleted, or that one or several amino acids are inserted or added.

6. (Original) The protein according to claim 5, which has the amino acid sequence shown in SEQ ID NO:3.

7. (Previously Presented) A protein comprising a region having the amino acid sequence recited in claim 1, which has an activity to transfer *N*-acetylglucosamine to a non-reducing terminal of Galβ1-4Glc or Galβ1-4GlcNAc group through β1,3-linkage.

8. (Currently Amended) ~~A~~An isolated nucleic acid coding for said protein according to claim 1.

9. (Original) The nucleic acid according to claim 8, which hybridizes with the nucleic acid having the nucleotide sequence shown in SEQ ID NO:2 or 4 under stringent conditions.

10. (Original) The nucleic acid according to claim 9, which has the nucleotide sequence shown in SEQ ID NO:2 or 4.

11. (Previously Presented) A recombinant vector comprising the nucleic acid according to claim 8, which can express said nucleic acid in a host cell.

12. (Previously Presented) A cell into which said nucleic acid according to claim 8 is introduced, which expresses said nucleic acid.

13. (Previously Presented) A nucleic acid for measurement of said nucleic acid according to claim 8, which specifically hybridizes with said nucleic acid according to claim 8.

14. (Previously Presented) The nucleic acid for measurement of nucleic acid, according to claim 13, which has a sequence complementary to a part of a nucleic acid having a nucleotide sequence as shown in SEQ ID NO:2 or 4.

15. (Original) The nucleic acid for measurement of nucleic acid, according to claim 13 or 14, which is a probe or a primer.

16. (Original) The nucleic acid for measurement of nucleic acid, according to claim 15, which has not less than 15 bases.

17-19. (Cancelled)

20. (Original) A method for diagnosis of a cancer and/or tumor, comprising determining the amount of said protein according to claim 6 or determining the expression amount of the gene coding for said protein, in (a) sample cell(s) separated from body.

21. (Original) The method according to claim 20, wherein said sample cell(s) is(are) originated from a digestive organ, and wherein said method is for diagnosis of a cancer and/or tumor of the digestive organ.

22. (Original) The method according to claim 21, wherein said sample cell(s) is(are) originated from colon, and wherein said method is for diagnosis of colon cancer.

23. (Previously Presented) A method for measuring said nucleic acid according to claim 8, comprising hybridizing the nucleic acid of claim 8, and measuring the hybridized nucleic acid.

24. (Previously Presented) A method for measuring said nucleic acid according to claim 8, comprising amplifying a nucleic acid by using as primers a pair of nucleic acids, and using as a template said nucleic acid according to claim 8, and measuring amplification product.

25. (Previously Presented) The method for diagnosis of a cancer and/or tumor according to claim 20, comprising hybridizing a nucleic acid, and mRNA transcribed from the gene of said protein having an amino acid sequence of SEQ ID NO:3 or cDNA generated by using said mRNA as a template, and measuring the hybridized nucleic acid, so as to measure the expression

amount of the gene of said protein.

26. (Previously Presented) The method for diagnosis of a cancer and/or tumor according to claim 20, comprising carrying out a nucleic acid-amplification method using as primers a pair of nucleic acids for measurement of nucleic acid, , and using as a template ~~the~~ mRNA transcribed from a gene of a protein having an amino acid sequence of SEQ ID NO:3 or cDNA generated by using said mRNA, and measuring amplification product, so as to measure the expression amount of the gene of said protein.

27-30. (Cancelled)